A forum for researchers, students and applicants in the field of cyclodextrin technology
Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric
Ligand Pharmaceuticals Incorporated presented positive results from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN
Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced
Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, announced
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders,
After years of slow growth, Amgen’s Kyprolis finally looks poised to break the blockbuster barrier in 2019, and new data
A new clinical trial with a rather innovative use of cyclodextrins is about to start shortly, although the recruitment has
Ligand Pharmaceuticals Incorporated announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol
Aldeyra Therapeutics Announced Results from the SOLACE Trial in Noninfectious Anterior Uveitis. The main points are: Statistical Significance Not Achieved
A recently posted phase 2 clinical trial (not yet recruiting) aims to evaluate the effect of ADV6209, a new oral
